Video Guide
Catalyst Database
Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.
Ticker
Drug | Disease (links)
Stage (next event)
Catalyst Date
THTX
PDUFA
Tesamorelin (F8 Formulation)
HIV-Associated Excess Abdominal Fat
March 25, 2025
Original PDUFA date 1/22/24. 1/24/24- Received CRL; FDA requested clarifications around CMC and add'l info related to immunogenicity. 11/26/24- Resubmitted sBLA. 12/10/24- FDA assigned PDUFA goal date of March 25, 2025.
Approval decision
Meeting
Biomedical meeting
American Association for Cancer Research (AACR)
Cancer
March 25, 2025
AACR abstract release date: Regular & Late-breaking Abstract title release on March 25th, 2025, and Regular Abstract text release on 3/25. Late-breaking texts are embargoed until April 25, 2025.
Abstract Release
SLNO
PDUFA
DCCR (Diazoxide Choline Controlled-Release) (K ATP agonist)
PWS (Prader-Willi syndrome)
March 27, 2025
Suspected Mover: 4/29/24- FDA BTD. Presentation at ENDO '24. 6/28/24- NDA submission. 8/27/28- NDA accepted w/ PDUFA date set 12/27/24. 10/8/24- FDA confirmed Adcom meeting not needed. 11/26/24- Extended review with new PDUFA date March 27, 2025.
Approval decision
MIST
PDUFA
Etripamil (CARDAMYST) (calcium channel blocker)
(PSVT) Paroxysmal Supraventricular Tachycardia
March 27, 2025
Big Mover: RAPID/RAPID Ext./NODE-303/NODE-301 studies. 5/29/24- NDA accepted. 8/26/24- NODE-303 data presentation at ESC '24 on 8/30/24. 11/12/24- PDUFA goal date of March 27, 2025.
Approval decision
Meeting
Biomedical meeting
American College of Cardiology (ACC) Annual Scientific Session
Cardiology
March 29-31, 2025
ACC.25 meeting dates: March 29-31, 2025. https://accscientificsession.acc.org/
Meeting dates
Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20